Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend:
Sanofi amends trial protocol
Sanofi has big plans for amlitelimab, the monoclonal antibody that binds to OX40-Ligand acquired in the $1.5 billion Kymab bolt-on from 2021. But first up is atopic dermatitis.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
